Recommendations by the MMHCC Mouse Models of Cutaneous Cancers
The following recommendations were unanimously agreed upon by the members of the
Think Tank based on the strong needs for this community in order to achieve the mission goals
of this consortium. Specifically, we need to:
1. Develop and optimize a standard set of markers for tumor and stromal compartments in
cutaneous cancer models for comprehensive characterization of tumors.
a. Funding for effort to evaluate the usefulness of currently available antibodies for
IHC in paraffin-embedded mouse tissues and optimize protocols
b. Funding for effort to develop new markers
2. Organize systematic efforts to screen for genomic and genetic changes in familial and
sporadic melanoma and non-melanoma skin cancers in human in order to facilitate efforts
in the mouse
a. Directed funding for such efforts in the form of supplement, R21/R33, or RFA.
3. Meet the urgent needs to improve genomic resources for this community:
a. BAC resources
i. Petition MMHCC Mouse BAC effort to prioritize identification and
mapping of BACs in loci known to be altered in human melanoma and
non-melanoma skin cancers
ii. Establish a mechanism for distribution of such BACs once identified.
b. Stage-specific expression libraries
i. Petition CGAP to generate and sequence cDNA and ESTs libraries for
various stages of melanocytic and keratinocytic transfomration
c. Directed funding to develop methodology for isolation and collection of normal
and pre-neoplastic melanocytes for generation of expression libraries.
i. Rationale: such tissue sources are not available given the few number of
melanocytes in normal skin, and the size and need for pathological
evaluation in entirety of pre-neoplastic and early dysplastic lesions.
4. Obtain acknowledge from the NIH that there are instances, such as in long-term outcome
study, where observation of mice with cutaneous tumors exceeding size limit but in good
health should be allowed.
5. Continuous annual think tank meetings to bring together scientists in both melanoma and
non-melanoma skin cancer fields.